Susquehanna International Group, LLP Prelude Therapeutics Inc Call Options Transaction History

Susquehanna International Group, LLP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $127,500 - $224,910	-25,500 Reduced 23.94%	81,000 $535,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $266,000 - $502,075	66,500 Added 166.25%	106,500 $556,000
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $276,000 - $528,800	40,000 New	40,000 $276,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $41.8M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.